Some patients find that remaining at a lower maintenance dose, whilst potentially sacrificing some glycaemic or weight loss benefits, provides an acceptable balance between efficacy and tolerability
Meziane H, Schaller F, Bauer S, Villard C, Matarazzo V, Riet F et al
Back Thorens, B, Hodson, DJ (2024) Building the glucagon-like peptide-1 receptor brick by brick: Revisiting a 1993 Diabetes Classic by Thorens et al, Diabetes, 73, 1027-31
This toner seamlessly complements any skincare routine, making it an indispensable addition for optimum results
19 The Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN) trials with semaglutide also demonstrated a reduction in HbA1c levels, body weight, and cardiovascular events in individuals with type 2 diabetes